5,6,7,8-四氢-8-氨基喹啉 | 298181-83-6

• 物质功能分类: 医药中间体 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 5,6,7,8-四氢-8-氨基喹啉
• 中文别名: 8-胺基-5,6,7,8-四氢喹啉
• 英文名称: 8-amino-5,6,7,8-tetrahydroquinoline
• 英文别名: 5,6,7,8-tetrahydroquinoline-8-amine；5,6,7,8-tetrahydroquinolin-8-yl amine；5,6,7,8-tetrahydroquinolin-8-amine
• CAS: 298181-83-6
• 化学式: C₉H₁₂N₂
• 分子量: 148.208
• InChiKey: JQGOUNFVDYUKMM-UHFFFAOYSA-N

物化性质

• 沸点：
  277.3±28.0 °C(Predicted)
• 密度：
  1.081±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933499090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5,6,7,8-Tetrahydroquinolin-8-amine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5,6,7,8-Tetrahydroquinolin-8-amine
CAS number: 298181-83-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H12N2
Molecular weight: 148.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5,6,7,8-四氢-8-氨基喹啉 在 6,7-二氢-5H-喹啉-8-酮 、 4 A molecular sieve 、 immobilized Candida antarctica Lipase B 、 水 作用下， 以 甲苯 为溶剂， 反应 48.0h， 生成 (8R)-5,6,7,8-四氢-8-氨基喹啉
  参考文献：
  名称：

  8-氨基-5,6,7,8-四氢喹啉的自发酶促动力学动力学拆分

  摘要：

  在南极假丝酵母脂肪酶B存在的情况下，观察到了8-氨基-5,6,7,8-四氢喹啉1的自发动态动力学拆分，其中（R）-乙酰胺[（R）-2]的收率> 60％从外消旋胺中分离出]。酮3的自发形成，然后通过烯胺4与其余（S）-胺1的缩合/水解过程提供了必要的消旋途径。

  DOI：

  10.1021/jo062037t
• 作为产物：
  描述：

  (8R)-5,6,7,8-四氢-8-氨基喹啉 反应 0.5h， 以87%的产率得到5,6,7,8-四氢-8-氨基喹啉
  参考文献：
  名称：

  Enzymatic Resolution of Bicyclic 1-Heteroarylamines Using Candida antarctica Lipase B

  摘要：

  Candida antarctica lipase B has been used to kinetically resolve a structurally diverse series of bicyclic 1-heteroaryl primary amines by enantioselective acetylation. High yields of either enantiomer could be obtained with excellent enantioselectivity (90-99% ee), while the undesired enantiomer could, in some cases be recycled by thermal racemization. The absolute stereochemistry of the products was confirmed by an X-ray crystal structure.

  DOI：

  10.1021/jo026701r

文献信息

• [EN] Pan-Tropic Entry Inhibitors<br/>[FR] INHIBITEURS D'ENTRÉE PANTROPIQUE
  申请人：UNIV EMORY

  公开号：WO2019183133A1

  公开（公告）日：2019-09-26

  This disclsore relates to compounds according to Formula (I), salts, prodrugs and pharmaceutical formulation comprising the compound are provided herein for the treatment of CXCR4 and CCR5 related conditions. The conditions may include viral infections, abnormal cellular proliferation, retinal degeneration and inflammatory diseases, or the compounds may be used as immunostimulants or immunosuppressants. Furthermore, the compounds may be used in combination with another active ingredient selected from an antiviral agent or chemotherapeutic agent.

  本公开涉及按照式(I)的化合物、盐、前药和含有该化合物的药物配方，用于治疗与CXCR4和CCR5相关的疾病。这些疾病可能包括病毒感染、异常细胞增殖、视网膜退化和炎症性疾病，或者这些化合物可以用作免疫刺激剂或免疫抑制剂。此外，这些化合物可以与另一种来自抗病毒药物或化疗药物的活性成分结合使用。
• An air and moisture tolerant iminotrihydroquinoline-ruthenium(<scp>ii</scp>) catalyst for the transfer hydrogenation of ketones
  作者：Jiaoyan Li、Yingmiao Ma、Zheng Wang、Qingbin Liu、Gregory A. Solan、Yanping Ma、Wen-Hua Sun

  DOI：10.1039/c8dt01919c

  日期：——

  with RuCl2(PPh3)3 at room temperature affords the ruthenium(II) chelate (8-NH2-C9H10N)RuCl2(PPh3)2 (E), in which the two triphenylphosphine ligands are disposed mutually cis. By contrast, when the reaction is performed at reflux ligand oxidation/dehydrogenation occurs along with cis–trans reorganization of the triphenylphosphines to form the 8-imino-5,6,7-trihydroquinoline-ruthenium(II) complex, (8

  8-氨基-5,6,7,8-四氢喹啉在室温下与RuCl 2（PPh 3）3反应得到钌（II）螯合物（8-NH 2 -C 9 H 10 N）RuCl 2（PPh 3）2（E），其中两个三苯基膦配体相互顺式排列。相反，当反应在回流条件下进行时，配体会发生氧化/脱氢以及三苯基膦的顺式-反式重组，形成8-亚氨基-5,6,7-三氢喹啉-钌（II）络合物，（8-NH C9 H 9 N）RuCl 2（PPh 3） 2（ F）。通过单独加热E溶液至回流，也可以高收率获得配合物F。它们的分子结构比较突出了F中的二齿亚胺配体比E中的含胺对应物优越的结合性能。两种络合物在多种烷基-，芳基-和环烷基的酮的转移氢化中非常有效，从而提供其相应的仲醇，其负载量低至0.1 mol％。明显地， F即使在与空气接触的反应釜中，即使是台式质量的2-丙醇也可以提供出色的转化率，而E的催化效率会因空气的存在而降低，但只能在惰性条件下有效地操作。
• ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT
  申请人：Centre National de la Recherche Scientifique

  公开号：US20210009581A1

  公开（公告）日：2021-01-14

  The present invention concerns a compound of following general formula (I): where: either R is an R 1 group and R′ is an -A 1 -Cy 1 group, or R is an -A 1 -Cy 1 group and R′ is an R 1 group, R 1 particularly being H or (C 1 -C 6 )alkyl group; A 1 being an —NH— radical or —NH—CH 2 — radical; Cy 1 particularly being a phenyl group, A is a fused (hetero)aromatic ring having 5 to 7 atoms, for use for treating cancer.

  本发明涉及以下一般式（I）的化合物： 其中： R是R1基团且R′是-A1-Cy1基团，或者R是-A1-Cy1基团且R′是R1基团， 其中R1特别是H或（C1-C6）烷基基团； A1是—NH—基团或—NH—CH2—基团； Cy1特别是苯基， A是具有5到7个原子的融合（杂）芳香环， 用于治疗癌症。
• Chemokine receptor binding heterocyclic compounds
  申请人：AnorMED, Inc.

  公开号：US06750348B1

  公开（公告）日：2004-06-15

  This invention relates to a novel class of heterocyclic compounds that bind chemokine receptors, inhibiting the binding of their natural ligands thereby. These compounds result in protective effects against infection by HIV through binding to chemokine receptors, including CXCR4 and CCR5, thus inhibiting the subsequent binding by these chemokines. The present invention provides a compound of Formula I wherein, W is a nitrogen atom and Y is absent or, W is a carbon atom and Y═H; R1 to R7 may be the same or different and are independently selected from hydrogen or straight, branched or cyclic C1-6 alkyl; R8 is a substituted heterocyclic group or a substituted aromatic group Ar is an aromatic or heteroaromatic ring each optionally substituted at single or multiple, non-linking positions with electron-donating or withdrawing groups; n and n′ are independently, 0-2; X is a group of the formula: Wherein, Ring A is an optionally substituted, saturated or unsaturated 5 or 6-membered ring, and P is an optionally substituted carbon atom, an optionally substituted nitrogen atom, sulfur or oxygen atom. Ring B is an optionally substituted 5 to 7-membered ring. Ring A and Ring B in the above formula can be connected to the group W from any position via the group V, wherein V is a chemical bond, a (CH2)n″ group (where n″=0-2) or a C═O group. Z is, (1) a hydrogen atom, (2) an optionally substituted C1-6 alkyl group, (3) a C0-6 alkyl group substituted with an optionally substituted aromatic or heterocyclic group, (4) an optionally substituted C0-6 alkylamino or C3-7 cycloalkylamino group, (5) an optionally substituted carbonyl group or sulfonyl. These compounds further include any pharmaceutically acceptable acid addition salts and metal complexes thereof and any stereoisomeric forms and mixtures of stereoisomeric forms thereof.

  这项发明涉及一类新型的杂环化合物，它们结合趋化因子受体，抑制其天然配体的结合。这些化合物通过结合趋化因子受体，包括CXCR4和CCR5，从而抑制这些趋化因子的后续结合，产生对HIV感染的保护效果。本发明提供了一个式I的化合物 其中，W是氮原子，Y不存在，或者W是碳原子，Y═H； R1至R7可以相同也可以不同，并且独立地选择自氢或直链、支链或环状的C1-6烷基； R8是一个取代的杂环基或取代的芳香基 Ar是一个芳香或杂芳环，每个环在单个或多个非连接位置可选择地取代有电子给体或吸引体基团； n和n′独立地为0-2； X是下式的一个基团： 其中，环A是一个可选择地取代的饱和或不饱和的5或6元环，P是一个可选择地取代的碳原子、一个可选择地取代的氮原子、硫或氧原子。环B是一个可选择地取代的5到7元环。上述式中的环A和环B可以通过基团V从任何位置连接到基团W，其中V是一个化学键，一个(CH2)n″基团（其中n″=0-2）或一个C═O基团。Z是(1)一个氢原子，(2)一个可选择地取代的C1-6烷基基团，(3)一个用可选择地取代的芳香或杂环基团取代的C0-6烷基基团，(4)一个可选择地取代的C0-6烷基氨基或C3-7环烷氨基基团，(5)一个可选择地取代的羰基或磺酰基。这些化合物还包括任何药学上可接受的酸盐和金属络合物，以及它们的任何立体异构体形式和立体异构体形式的混合物。
• Chemokine receptor binding heterocyclic compounds with enhanced efficacy
  申请人：——

  公开号：US20030220341A1

  公开（公告）日：2003-11-27

  The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

  这项发明涉及由一个核心氮原子环绕着三个侧链基团的杂环化合物，其中三个侧链基团中的两个最好是苯并咪唑甲基和四氢喹啉基，第三个侧链基团含有N，并且可选地含有额外的环。这些化合物与趋化因子受体结合，包括CXCR4和CCR5，并且表现出对人类免疫缺陷病毒（HIV）感染靶细胞的保护作用。